Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

For Patients: Seralutinib for the Treatment of Pulmonary Arterial Hypertension: Results From the Phase 3 PROSERA Trial

Friday, June 12, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the results of the Phase 3 PROSERA trial for Seralutinib, a treatment for pulmonary arterial hypertension (PAH). The trial's findings indicate positive outcomes, suggesting that Seralutinib may be an effective option for patients suffering from this condition. The article emphasizes the importance of these results for future treatment pathways.
Price reaction · baseline $0.1774 (2026-06-11 close) · hit pre-market · 1 other GOSS headline(s) in the window, move may be shared
day 0 close · peak
-8.7%
day 1
-5.9%
day 3
+0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib shows promise for treating pulmonary arterial hypertension.
  • The Phase 3 PROSERA trial results are encouraging for patients.
  • Potential for expanded access to treatment options.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

For Patients: Seralutinib for the Treatment of Pulmonary Arterial Hypertension: Results From the Phase 3 PROSERA Trial
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is Seralutinib used for?

Seralutinib is used for the treatment of pulmonary arterial hypertension (PAH).

What were the results of the PROSERA trial?

The PROSERA trial results indicated positive outcomes for patients treated with Seralutinib.

Is Seralutinib available for patients?

The article suggests potential for expanded access to Seralutinib for patients.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib pulmonary arterial hypertension PAH PROSERA trial clinical trial
Last updated: Jun 12, 2026

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →